Case number 1:22-cv-01480
Taiho Pharmaceutical Co., Ltd. et al v. Natco Pharma Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 11, 2024 | 29 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,456,399 B2; 10,960,004 B2. (Attachments: # 1 Stipulation of Dismissal)(ceg) (Entered: 04/11/2024) (0) |
| Apr 11, 2024 | 28 | SO ORDERED, re 27 Stipulation of Dismissal with Prejudice. (***Civil Case Terminated). Signed by Judge Jennifer L. Hall on 4/11/2024. (ceg) (Entered: 04/11/2024) (3) |
| Apr 5, 2024 | 27 | STIPULATION of Dismissal with Prejudice between Plaintiffs and Defendants Natco Pharma Ltd. and Natco Pharma, Inc., by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. (Biggs, Brian) Modified on 4/5/2024 (ceg). (Main Document 27 replaced on 4/11/2024) (ceg). (Entered: 04/05/2024) (3) |
| Feb 23, 2024 | 26 | NOTICE to Take Deposition of Robert E. Winkler on March 7, 2024 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) (Entered: 02/23/2024) (2) |
| Nov 17, 2023 | 25 | CONSENT to Jurisdiction by U.S. Magistrate Judge filed by Natco Pharma Ltd., Natco Pharma, Inc., Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. Case reassigned to Magistrate Judge Jennifer L. Hall. Signed by Judge Colm F. Connolly on 11/17/2023. (nmf) (Entered: 11/17/2023) (6) |
| Nov 16, 2023 | 24 | NOTICE of Subpoena to Robert E. Winkler, Ph.D. by Natco Pharma Ltd., Natco Pharma, Inc. (Attachments: # 1 Subpoena to Testify at Deposition)(Farnan, Kelly) (Entered: 11/16/2023) (0) |
| Aug 25, 2023 | 23 | NOTICE OF SERVICE of Plaintiffs First Supplemental Objections and Responses to Defendants Joint First Set of Interrogatories (Nos. 1-4) (Supplementing Interrogatory No. 3) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Whitesell, Angela) (Entered: 08/25/2023) (3) |
| Apr 6, 2023 | 22 | STIPULATION and [Proposed] Order to Extend Certain Scheduling Order Deadlines by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 04/06/2023) (6) |
| Mar 29, 2023 | 21 | NOTICE OF SERVICE of Defendants Natco Pharma Inc.'s and Natco Pharma, Ltd.'s Initial Disclosures pursuant to the Delaware Default Standard Paragraph 3 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Cragg, Tyler) (Entered: 03/29/2023) (2) |
| Feb 28, 2023 | N/A | Case associated with lead case: Create association to 1:21-cv-00838-CFC. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 21-838-CFC ONLY. (nmf) (Entered: 02/28/2023) (0) |
| Feb 28, 2023 | 20 | SCHEDULING & CONSOLIDATION ORDER: Civil Action No. 21-838-CFC shall be the lead case and all future filings shall be made in Lead Case No. 21-838-CFC ONLY. Joinder of Parties due by 6/16/2023. Amended Pleadings due by 6/16/2023. Fact Discovery completed by 9/29/2023. Expert Discovery due by 2/29/2024. Signed by Judge Colm F. Connolly on 2/28/2023. Associated Cases: 1:21-cv-00838-CFC, 1:22-cv-01480-CFC, 1:22-cv-01611-CFC, 1:23-cv-00008-CFC(nmf) (Entered: 02/28/2023) (25) |
| Feb 27, 2023 | 19 | PROPOSED ORDER (Proposed Scheduling Order), by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 02/27/2023) (25) |
| Feb 27, 2023 | 18 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Proposed Scheduling Order. (Balick, Steven) (Entered: 02/27/2023) (2) |
| Feb 15, 2023 | N/A | Pro Hac Vice Attorney Andrew O. Larsen, Christopher J. Sorenson, and Jason M. Wiener for Natco Pharma Ltd. and Natco Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/15/2023) (0) |
| Feb 13, 2023 | 17 | SO ORDERED, re (13 in 1:22-cv-01611-CFC, 16 in 1:22-cv-01480-CFC) STIPULATION TO EXTEND TIME proposed scheduling order to February 27, 2023, filed by Natco Pharma Ltd., Natco Pharma, Inc. Resetting Deadlines: Notice of Compliance deadline set for 2/27/2023. Signed by Judge Colm F. Connolly on 2/13/2023. Associated Cases: 1:22-cv-01480-CFC, 1:22-cv-01611-CFC(kmd) (Entered: 02/13/2023) (4) |
| Feb 10, 2023 | 16 | STIPULATION TO EXTEND TIME proposed scheduling order to February 27, 2023 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 02/10/2023) (4) |
| Feb 7, 2023 | N/A | Pro Hac Vice Attorney Andrew O. Larsen for Natco Pharma Ltd. and Natco Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) (Entered: 02/07/2023) (0) |
| Feb 6, 2023 | N/A | SO ORDERED, re 15 MOTION for Pro Hac Vice Appearance of Attorney Christopher J. Sorenson, Andrew O. Larsen, and Jason M. Wiener, filed by Natco Pharma Ltd., Natco Pharma, Inc. Ordered by Judge Colm F. Connolly on 2/6/2023. (kmd) (Entered: 02/06/2023) (0) |
| Feb 6, 2023 | N/A | Pro Hac Vice Attorney Christopher J. Sorenson and Jason M. Wiener for Natco Pharma Ltd. and Natco Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/06/2023) (0) |
| Feb 3, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Christopher J. Sorenson, Andrew O. Larsen, and Jason M. Wiener - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 02/03/2023) (5) |
| Feb 3, 2023 | 14 | NOTICE of Appearance by Tyler E. Cragg on behalf of Natco Pharma Ltd., Natco Pharma, Inc. (Cragg, Tyler) (Entered: 02/03/2023) (2) |
| Jan 12, 2023 | 13 | ORDER, having been assigned these cases which are listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before February 13, 2023, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed. ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 2/13/2023.) Signed by Judge Colm F. Connolly on 1/12/2023. Associated Cases: 1:22-cv-01480-CFC, 1:22-cv-01611-CFC, 1:23-cv-00008-CFC(nmf) (Entered: 01/12/2023) (2) |
| Jan 10, 2023 | 12 | ANSWER to 1 Complaint by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) (Entered: 01/10/2023) (30) |
| Jan 4, 2023 | 11 | SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc..Natco Pharma Ltd. served on 1/3/2023, answer due 1/24/2023. (Balick, Steven) (Entered: 01/04/2023) (2) |
| Dec 28, 2022 | 10 | STANDING ORDER REGARDING BRIEFING IN ALL CASES. Associated Cases: 1:22-cv-01611-CFC et al.(kmd) (Entered: 12/28/2022) (2) |
| Dec 27, 2022 | 9 | REDACTED VERSION of (109 in 1:19-cv-02321-CFC, 99 in 1:19-cv-02309-CFC, 21 in 1:21-cv-00838-CFC, 8 in 1:22-cv-01480-CFC, 131 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02368-CFC-JLH) Letter by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 12/27/2022) (8) |
| Dec 20, 2022 | 8 | [SEALED] Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Submission Concerning Issues Relevant to the December 21 Status and Scheduling Conference. (Balick, Steven) (Entered: 12/20/2022) (0) |
| Dec 16, 2022 | 7 | SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc..Natco Pharma, Inc. served on 12/16/2022, answer due 1/6/2023. (Balick, Steven) (Entered: 12/16/2022) (2) |
| Nov 16, 2022 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 11/16/2022) (0) |
| Nov 10, 2022 | 1 | COMPLAINT filed against Natco Pharma Ltd., Natco Pharma, Inc. ( Filing fee $ 402, receipt number ADEDC-4003046.) - filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(apk) (Entered: 11/10/2022) (Exhibit A-C) (30) |
| Nov 10, 2022 | 1 | COMPLAINT filed against Natco Pharma Ltd., Natco Pharma, Inc. ( Filing fee $ 402, receipt number ADEDC-4003046.) - filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(apk) (Entered: 11/10/2022) (Civil Cover Sheet) (2) |
| Nov 10, 2022 | N/A | No Summons Issued. (apk) (Entered: 11/10/2022) (0) |
| Nov 10, 2022 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Pharmaceutical Co., Ltd. filed by Taiho Pharmaceutical Co., Ltd. (apk) (Entered: 11/10/2022) (2) |
| Nov 10, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd., Corporate Parent Taiho Pharmaceutical Co., Ltd. for Taiho Oncology, Inc. filed by Taiho Oncology, Inc. (apk) (Entered: 11/10/2022) (2) |
| Nov 10, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,456,399 B2 ;10,960,004 B2. (apk) (Entered: 11/10/2022) (1) |
| Nov 10, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/4/2022. Date of Expiration of Patent: 2/3/37 .Thirty Month Stay Deadline: 3/23/2023. (apk) (Entered: 11/10/2022) (2) |
| Nov 10, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) (Entered: 11/10/2022) (3) |
| Nov 10, 2022 | 1 | COMPLAINT filed against Natco Pharma Ltd., Natco Pharma, Inc. ( Filing fee $ 402, receipt number ADEDC-4003046.) - filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(apk) (Entered: 11/10/2022) (Main Document) (30) |
